Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement.
Montplaisir
J
J
Department of Psychiatry, University of Toronto, ECW-3D Bathurst Street, Toronto, Ontario M5T 2SB, Canada.
Hawa
R
R
Moller
H
H
Morin
C
C
Fortin
M
M
Matte
J
J
Reinish
L
L
Shapiro
C M
CM
D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D053961:Azabicyclo Compounds; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D002170:Canada; D032921:Consensus; D004347:Drug Interactions; D017723:Drug Utilization Review / Q000592:standards; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*
D000081:Acetamides; D014151:Anti-Anxiety Agents; D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; D011743:Pyrimidines; C515050:zopiclone; D001569:Benzodiazepines; C085665:zaleplon